

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 8-K

REGENERON PHARMACEUTICALS INC  
Form 8-K  
May 13, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2010 (May 12, 2010)

REGENERON PHARMACEUTICALS, INC.  
(Exact Name of Registrant as Specified in Charter)

|   |                       |                                   |
|---|-----------------------|-----------------------------------|
| New York  | 000-19034             | 13-3444607                        |
| (State or other jurisdiction of<br>Incorporation) | (Commission File No.) | (IRS Employer Identification No.) |

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707  
(Address of principal executive offices, including zip code)

(914) 347-7000  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- c Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - c Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - c Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - c Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 8-K

### Item 8.01 Other Events.

On May 12, 2010, Regeneron Pharmaceuticals, Inc. issued a press release reporting preliminary clinical trial results for two antibody product candidates in development, REGN727, a fully human antibody that targets Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), and REGN475, a fully human antibody that targets nerve growth factor (NGF). A copy of this press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

### Item 9.01 Financial Statements and Exhibits.

#### (d) Exhibits

99.1 Press Release dated May 12, 2010.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 13, 2010

REGENERON PHARMACEUTICALS, INC.

By: /s/ Stuart Kolinski  
Name: Stuart Kolinski  
Title: Senior Vice President and General Counsel

---

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 8-K

Exhibit Index

| Exhibit No. | Description                       |
|-------------|-----------------------------------|
| 99.1        | Press Release dated May 12, 2010. |

---